Navigation Links
Multiple Dose Clinical Trial of TorreyPines Therapeutics' Tezampanel Demonstrates Compound is Safe and Well-Tolerated
Date:2/5/2008

lecules. The company is developing versatile product candidates, each potentially capable of treating a number of different diseases and disorders, including chronic pain, muscle spasticity and rigidity, cognitive disorders and xerostomia, or dry mouth. Further information is available at http://www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions. Such forward-looking statements include statements regarding the potential for tezampanel as a treatment for migraine, the potential for NGX426 as a treatment for migraine, the potential for tezampanel to offer a unique approach to the management of pain, the potential for tezampanel or NGX426 to offer a unique approach to the management of pain and the potential timing, development and initiation of future clinical trials of tezampanel and NGX426. Such statements are subject to numerous risks, and uncertainties that may cause actual events or results to differ materially from the company's current expectations. Statements regarding TorreyPines Therapeutics' product candidates are subject to risks and uncertainties regarding development, regulatory approval and commercialization, including whether the results of the Phase IIb trial are predictive of results in subsequent trials of tezampanel, whether the results of the Phase I trial are predictive of results in subsequent trials of tezampanel or NGX426, whether further testing of tezampanel and NGX426 will result in data sufficient to support regulatory approval, whether AMPA/kainate antagonists will prove to be safe and effective treatments for migraine and other pain conditions as well as non-pain conditions, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its drug candidates
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
2. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
3. Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R)
4. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
5. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
6. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
7. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
8. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
9. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
10. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
11. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... -- In response to an FDA notice ... the Agency recommended that healthcare facilities discontinue use ... system, hospitals throughout the U.S. are faced with ... product. According to the FDA, STERIS made changes ... affect the safety or the effectiveness of the ...
(Date:12/14/2009)... is a statement by Linda A. Suydam, D.P.A., ... regarding today,s release of the National Institute on ... "Findings released today on this year,s Monitoring the ... efforts to educate and empower parents with the ... about medicine abuse. The Consumer Healthcare Products Association ...
(Date:12/14/2009)... directors of Eli Lilly and Company (NYSE: ... quarter of 2010 of $0.49 a share on outstanding ... March 10, 2010 to shareholders of record at the ... ,, Lilly, a leading innovation-driven corporation, is developing a ... research from its own worldwide laboratories and from collaborations ...
Breaking Medicine Technology:ECRI Institute Issues Steris System 1 High Priority Alert and Recommendations: Free Guidance to Help Hospitals Map out Transition to Alternative Reprocessing Methods 2ECRI Institute Issues Steris System 1 High Priority Alert and Recommendations: Free Guidance to Help Hospitals Map out Transition to Alternative Reprocessing Methods 3Statement From the Consumer Healthcare Products Association(CHPA) on Annual Monitoring the Future Survey on Drug Abuse 2Statement From the Consumer Healthcare Products Association(CHPA) on Annual Monitoring the Future Survey on Drug Abuse 3UM receives grant to support graduate students in the family nurse practitioner program 56850 1UM receives grant to support graduate students in the family nurse practitioner program 56850 2Dividing cells feel their way out of warp 9878 1Dividing cells feel their way out of warp 9878 2Oil and wildlife dont mix in Ecuadors Eden 9876 1Oil and wildlife dont mix in Ecuadors Eden 9876 2Oil and wildlife dont mix in Ecuadors Eden 9876 3
... compared to,sumatriptan, RESEARCH TRIANGLE PARK and CHAPEL ... Findings from two pivotal efficacy,studies of more ... superior headache relief at two hours and ... 24-hour sustained,pain-free results versus sumatriptan or naproxen ...
... CytImmune, a,clinical stage nanomedicine company focused on the ... to present a poster abstract at the 43rd ... Illinois,June 1-5. The poster session will take place ... Dr. Lawrence Tamarkin, CEO of CytImmune will,present the ...
Other Medicine Technology:Trexima (Sumatriptan/Naproxen Sodium) Superior Efficacy Data,Published in JAMA 2Trexima (Sumatriptan/Naproxen Sodium) Superior Efficacy Data,Published in JAMA 3Trexima (Sumatriptan/Naproxen Sodium) Superior Efficacy Data,Published in JAMA 4Trexima (Sumatriptan/Naproxen Sodium) Superior Efficacy Data,Published in JAMA 5CytImmune To Present At ASCO Phase I Clinical Trial of CYT-6091 to,be Presented on June 3, 2007 2
(Date:12/15/2009)... based on health status categories and corresponding plan benefits. ... ... 14, 2009 -- Physicians Health Choice is one of only ... and value in the design of their 2010 medical and ... Medicare Advantage company won for its Standard plans in Austin, ...
(Date:12/15/2009)... businesses with large areas where people gather, need to have ... rescue personnel agree that for any size business, agency or ... ... Issaquah, WA (PRWEB) December 15, 2009 -- ... with large areas where people gather, need to have an ...
(Date:12/15/2009)... Ill. A study in the Dec. 15 issue ... shows that being overweight or obese increases the risk ... not in younger children. , Results indicate ... years of age and older increased 3.5 fold with ... while the risk of OSA did not significantly increase ...
(Date:12/14/2009)... OAK BROOK, Ill., Dec. 15 In ... a larger role than ever. Now the University ... noteworthy resources, Value Analysis: Achieving Cost Efficiencies ... staff in these complex environments. These new materials, ... in the field, provide a practical guide to ...
(Date:12/14/2009)... and HOLLYWOOD, Fla., Dec. 14 ... today a definitive agreement to acquire STARLIMS ... leading provider of laboratory information management systems, ... ,, The acquisition strengthens Abbott,s competitive position ... web-based applications to help laboratories efficiently store, ...
Breaking Medicine News(10 mins):Health News:Physicians Health Choice Receives Senior Choice Gold Award for 2010 Medicare Plan Benefits 2Health News:Physicians Health Choice Receives Senior Choice Gold Award for 2010 Medicare Plan Benefits 3Health News:Physicians Health Choice Receives Senior Choice Gold Award for 2010 Medicare Plan Benefits 4Health News:QuickMedical Responds to Oregon Bill Requiring Businesses to Carry Defibrillators 2Health News:QuickMedical Responds to Oregon Bill Requiring Businesses to Carry Defibrillators 3Health News:Obesity increases the risk for obstructive sleep apnea in adolescents, but not in younger children 2Health News:University HealthSystem Consortium Offers Value Analysis Professionals Insightful New Resources 2Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 2Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 3Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 4
... BOCA RATON, Fla., March 9 "You have Multiple Sclerosis and ... may not have the symptoms today, but it is just a ... heard from his doctor in 2002. In his new book, "Don,t ... AuthorHouse ), Knapp lets the reader peek inside the unusual world ...
... says regular colon cancer screening should start at age 50ANN ... talk about colons behind the bathroom door.It,s time to talk, ... the University of Michigan Health System.Regular wear and ... in one in three adults over the age of 65. ...
... March 9 Hooper Holmes (Amex: HH ) ... end 2008 financial results before market on Friday, March 13, ... Friday, March 13, 2009 at 11:00am Eastern Time. ... call, please dial 888-790-3758 or 210-839-8398, pass code: Hooper Holmes. ...
... the ,baby blues, and postnatal depression, some may be surprised to hear ... to as ,antenatal depression., Gurgle.com tells you how to spot the ... you experience any of these conditions. , ... London, England (PRWEB) February ...
... March 9 Victory Pharma, Inc. ("Victory" or "the ... that it has closed on a $45 million equity ... Ampersand Ventures, an existing investor, also participated in ... future growth initiatives, including product acquisitions. As part ...
... Take a Second Look at Patent in a Reexamination Procedure, ... March 9 Article One Partners LLC has discovered new ... U.S. drug patent. A request is being filed today with ... reexamination proceeding. An independent law firm and an independent expert ...
Other Medicine News:Health News:'Don't Ask Me How I Feel, I Have MS' 2Health News:Keep Your Colon Healthy With Exercise, Healthy Foods 2Health News:Keep Your Colon Healthy With Exercise, Healthy Foods 3Health News:Hooper Holmes Announces Fourth Quarter Earnings Release Date and Conference Call Information 2Health News:Gurgle.com Explains How to Spot the Signs of Antenatal and Postnatal Depression 2Health News:Gurgle.com Explains How to Spot the Signs of Antenatal and Postnatal Depression 3Health News:Gurgle.com Explains How to Spot the Signs of Antenatal and Postnatal Depression 4Health News:Victory Pharma Announces $45 Million Equity Financing 2Health News:Article One Partners Uncovers New Prior Art Impacting the Validity of Merck's SINGULAIR Patent 2Health News:Article One Partners Uncovers New Prior Art Impacting the Validity of Merck's SINGULAIR Patent 3Health News:Article One Partners Uncovers New Prior Art Impacting the Validity of Merck's SINGULAIR Patent 4
A convenient, rotating standholds up to seven Gilson pipettes (any model) with exceptional stability. Protects your precious pipettes from possible damage or contamination....
Inquire...
... an automated solution for scheduling, performing and ... for all pipettes and liquid handling devices. ... Supports all gravimetric calibration protocols ... ISO 9000, NCCLS and GLP requirements ...
... • V-shaped bottom allows easy ... or 5 per bag ,• Corner ... Pipettor Solution Basin designed for 4, 8, ... V-shaped bottom permits withdrawal of practically all ...
Medicine Products: